CNTA•benzinga•
FDA Grants Orphan Drug Status To Centessa's Hemophilia B Candidate
Summary
Centessa Pharmaceuticals (NASDAQ: CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B. A Phase 2a proof-of-concept study evaluated SerpinPC in severe hemophilia A and B patients not on prophylaxis.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 14, 2022 by benzinga